TNF Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Significant Accounting Policies (Tables)

Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)		Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2)		Significant Unobservable Inputs (Level 3)
Marketable securities at December 31, 2019	$	-	$	9,164,273	$	-

Marketable securities at December 31, 2018	$	-	$	5,272,998	$	-

Schedule of Estimated Useful Life of Property Plant and Equipment

The estimated useful lives for the current and comparative periods are as follows:

		Useful Life
		(in years)
Plant and equipment		5-12
Furniture and fixtures		5-10
Computer equipment & software		3-5
Leasehold Improvements		Shorter of the remaining lease or estimated useful life

Schedule of Estimated Useful Life of Other Intangible Assets

The estimated useful lives for the current and comparative periods are as follows:

		Useful Life
		(in years)
Patents and trademarks		12-17

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share

The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:

	For the Years Ended December 31,
	2019		2018
Stock Options		40		443
Restricted Stock Units		15,603		-
Warrants to purchase Common Stock		247,215		88,015
Pre-funded Warrants to purchase Common Stock		795,000		-
Warrants to purchase Series C Preferred stock		1,990,000		-
Total potentially dilutive shares		3,047,858		88,458